Company Description
Procaps Group S.A. develops, produces, and markets pharmaceutical solutions worldwide.
The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory.
It also provides drugs for hospital use, such as antibiotic, blood clot, personal protective equipment, immunosuppressant, oncology, and analgesics products.
In addition, the company offers over-the-counter (OTC) consumer healthcare products through a portfolio on approximately eight therapeutic areas, including gastrointestinal, skin care, cough and cold, analgesics, urological, vitamins, minerals, and supplements in the categories of antibiotics, anti-infective, anti-parasitic, cardiovascular, feminine care, cutaneous antimycotic, pain killers, gastro intestinal, hormonals, metabolic, endocrine, nervous system, ophthalmic, osteoarticular, respiratory, diet supplements, and vitamins and minerals.
Further, it provides blood glucose meters, telemonitoring products, oral anti-diabetics products, cosmeceuticals, insulin delivery systems, and other diabetes solutions; and contract drug development and manufacturing services to third party pharmaceutical companies, specializing in soft gelatin capsule technologies.
The company was founded in 1977 and is based in Luxembourg, Luxembourg.
| Country | Luxembourg |
| Founded | 1976 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 5,500 |
| CEO | Jose Antonio Vieira |
Contact Details
Address: 9 Rue de Bitbourg Luxembourg, 1273 Luxembourg | |
| Phone | 356 7995 6138 |
| Website | procapsgroup.com |
Stock Details
| Ticker Symbol | PROC |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001863362 |
| CUSIP Number | L7756P102 |
| ISIN Number | LU2376511205 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Jose Antonio Toledo Vieira | Chief Executive Officer |
| Patricio Vargas Munoz | Global Chief Financial Officer |
| Dr. Camilo Camacho | Chief Operations Officer |
| Melissa Angelini | Investor Relations Director |
| Marcela Carvajalino Pagano | Vice-President of Corporate and Legal Affairs |
| Luis Alberto Palacios Aragon | Vice-President of International Marketing and Research & Development |
| Mauricio Castaneda Caballero | Vice-President of Human Resources |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 20, 2024 | 6-K | Report of foreign issuer |
| Dec 3, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Dec 3, 2024 | 6-K | Report of foreign issuer |
| Nov 29, 2024 | 6-K | Report of foreign issuer |
| Nov 15, 2024 | 6-K | Report of foreign issuer |
| Nov 1, 2024 | 6-K | Report of foreign issuer |
| Oct 29, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Oct 28, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Oct 10, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Oct 10, 2024 | 6-K | Report of foreign issuer |